SCHEMBL2846932

SCHEMBL2846932

CC(C)(C)OC(=O)NCC[C@H](N)C(=O)N1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CTSL P07711 3/20 0.44
CTSB P07858 3/20 0.44
CTSD P07339 2/20 0.44
CTSS P25774 2/20 0.44
CTSK P43235 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CD274 Q9NZQ7 1/20 0.43
GAA P10253 1/20 0.43
RECQL P46063 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
CASR P41180 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
HTT P42858 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2846938 1.00 USP2 (0.46) USP2SMN1; SMN2CTSLCTSBCTSD
SCHEMBL19707910 0.91 MEN1 (0.46) USP2SMN1; SMN2CTSLCTSBCTSD
SCHEMBL6792312 0.87 DPP7 (0.46) CTSKMEN1KMT2AGAATDP1
SCHEMBL14282734 0.84 USP2 (0.44) USP2SMN1; SMN2CTSLCTSBCTSD
SCHEMBL951878 0.82 MEN1 (0.43) SMN1; SMN2MEN1KMT2AGAARECQL
SCHEMBL951877 0.82 MEN1 (0.43) SMN1; SMN2MEN1KMT2AGAARECQL
SCHEMBL2852709 0.82 CD274 (0.43) USP2SMN1; SMN2CTSLCTSBCTSD
SCHEMBL2852705 0.82 CD274 (0.43) USP2SMN1; SMN2CTSLCTSBCTSD
SCHEMBL13598863 0.81 MEN1 (0.54) CTSKMEN1KMT2AGAATDP1
SCHEMBL19478686 0.79 SMN1; SMN2 (0.51) USP2SMN1; SMN2CTSLCTSBCTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362236-B2 Macrocyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2013-01-29 US disclosed
US-8362236-B2 Macrocyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2013-01-29 US disclosed
US-8362236-B2 Macrocyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2013-01-29 US disclosed
EP-2119718-B1 MACROCYCLIC COMPOUND CHUGAI PHARMACEUTICAL CO LTD (JP) 2012-04-11 EP disclosed
EP-2119718-B1 MACROCYCLIC COMPOUND CHUGAI PHARMACEUTICAL CO LTD (JP) 2012-04-11 EP disclosed
US-20100056510-A1 Macrocyclic Compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-04 US disclosed
US-20100056510-A1 Macrocyclic Compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-04 US disclosed
US-20100056510-A1 Macrocyclic Compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-04 US disclosed
EP-2119718-A1 MACROCYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2009-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056510-A1 Macrocyclic Compound HSP90AB1, HSP90B1, HSP90AA1 USP2 1771/4885SMN1; SMN2 4555/4885CTSL 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.